中国神经再生研究(英文版)

中国神经再生研究(英文版) ›› 2022, Vol. 17 ›› Issue (4): 875-880.doi: 10.4103/1673-5374.322476

• 原著:退行性病与再生 • 上一篇    下一篇

散发性肌萎缩侧索硬化中中性粒细胞与淋巴细胞的比率

  

  • 出版日期:2022-04-15 发布日期:2021-10-18

Neutrophil-to-lymphocyte ratio in sporadic amyotrophic lateral sclerosis

Qian-Qian Wei, Yan-Bing Hou, Ling-Yu Zhang, Ru-Wei Ou, Bei Cao, Yong-Ping Chen, Hui-Fang Shang*   

  1. Department of Neurology, Laboratory of Neurodegenerative Disorders, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China
  • Online:2022-04-15 Published:2021-10-18
  • Contact: Hui-Fang Shang, MD, hfshang2002@126.com.
  • Supported by:
    This study was supported by the Science and Technology Bureau Fund of Sichuan Province of China, No. 2020YFS0220; the China Postdoctoral Science Foundation, No. 2019M653427; Postdoctoral Research Project, West China Hospital, Sichuan University of China, No. 2019HXBH029; and Health Commission of Sichuan Province of China, No. 20PJ038 (all to QQW). 

PDF

102

摘要：

中性粒细胞与淋巴细胞的比率被认为是一种能预测多种疾病患者生存结局的可靠的生物标志物，但其是否也可作为肌萎缩侧索硬化的标志物仍有待研究。为探索散发性肌萎缩侧索硬化症患者中性粒细胞与淋巴细胞的比率与疾病进展及生存率的关系，试验于2012年1月至2018年12月纳入1030例肌萎缩侧索硬化患者，并基于中性粒细胞与淋巴细胞的比率将患者分为3组(< 2，2-3，> 3)，患者数量分别为544例（52.8%）、314例（30.5%）和172例（16.7%），随访至2020年4月。可见第3组患者起病年龄明显偏大，肌萎缩侧索硬化功能评分量表评分较低，病情进展迅速。调整其他危险因素后显示，较快的疾病进展率与较高的中性粒细胞与淋巴细胞的比率相关(OR=1.211, 95%CI:1.090-1.346，P<0.001)。与其他2组相比，第3组患者的生存时间较短(log-rank P=0.002)。在归一化所有其他因素后，中性粒细胞与淋巴细胞的比率被认为是预测肌萎缩侧索硬化患者生存率的独立因素(HR=1.079, 95%CI:1.016-1.146, P=0.014)。调整治疗(HR=1.074, 95%CI:1.012-1.141, P trend =0.019)或分层中性粒细胞与淋巴细胞的比率(HR=1.115, 95%CI: 1.009-1.232, P trend =0.033)也对肌萎缩侧索硬化生存率存在明显影响。因此中性粒细胞与淋巴细胞的比率可能预测散发性肌萎缩侧索硬化的疾病进展率和生存率。试验于2015年12月23日经四川大学华西医院伦理委员会批准（批准号2015（236））。

https://orcid.org/0000-0003-0947-1151 (Hui-Fang Shang)

关键词: 肌萎缩侧索硬化, 中性粒细胞, 淋巴细胞, 炎症, 预后, Cox分析, 存活率, 单核细胞

Abstract: The neutrophil-to-lymphocyte ratio (NLR) is considered a robust prognostic biomarker for predicting patient survival outcomes in many diseases. However, it remains unclear whether it can be used as a biomarker for amyotrophic lateral sclerosis (ALS). To correlate NLR with disease progression and survival in sporadic ALS, 1030 patients with ALS between January 2012 and December 2018 were included in this study. These patients were assigned into three groups according to their NLR values: Group 1 (NLR < 2, n = 544 [52.8%]), Group 2 (NLR = 2–3, n = 314 [30.5%]), and Group 3 (NLR > 3, n = 172 [16.7%]). All patients were followed up until April 2020. Patients in Group 3 had a significantly older onset age, a lower score on the Revised ALS Functional Rating Scale, and rapidly progressing disease conditions. Furthermore, faster disease progression rates were associated with higher NLR values (odds ratio = 1.211, 95% confidence interval [CI]: 1.090–1.346, P < 0.001) after adjusting for other risk factors. Compared with Groups 1 and 2, the survival time in Group 3 was significantly shorter (log-rank P = 0.002). The NLR value was considered an independent parameter for the prediction of survival in ALS patients after normalizing for all other potential parameters (hazard ratio [HR] = 1.079, 95% CI: 1.016–1.146, P = 0.014). The effects on ALS survival remained significant when adjusted for treatment (HR = 1.074, 95% CI: 1.012–1.141, Ptrend = 0.019) or when considering the stratified NLR value (HR = 1.115, 95% CI: 1.009–1.232, Ptrend = 0.033). Thus, the NLR may help to predict the rate of disease progression and survival in patients with sporadic ALS. The study was approved by the Institutional Ethics Committee of West China Hospital of Sichuan University, China (approval No. 2015 (236)) on December 23, 2015.

Key words: amyotrophic lateral sclerosis, Cox analysis, inflammation, lymphocytes, monocytes, neutrophils, prognosis, survival rate

中图分类号: